Is Bosutinib available in China?

Bosutinib (Bosutinib) is a tyrosine kinase inhibitor mainly used to treat chronic myelogenous leukemia (CML). CML is a type of leukemia caused by the BCR-ABL fusion gene, which produces an abnormal tyrosine kinase, leading to abnormal cell proliferation. Bosutinib works by inhibiting the activity of this abnormal kinase, thereby preventing the growth and division of leukemia cells.

Bosutinib was approved by the U.S. Food and Drug Administration (FDA) in in 2012, becoming one of the first-line treatment options for chronic myelogenous leukemia. Compared with other tyrosine kinase inhibitors, bosutinib performs better in selectivity and helps reduce adverse effects on normal cells.

This medicine is usually taken in oral form and patients need to take it on time according to the doctor's advice. During treatment, doctors will monitor the patient's blood indicators and physical condition to ensure the safety and effectiveness of the drug, and make adjustments as needed.

Although bosutinib has been successful in the treatment ofCML, it is not suitable for all patients and may cause some side effects, such as nausea, diarrhea, fatigue, etc. Therefore, during use, doctors and patients need to work closely together to weigh the pros and cons of treatment.

Bosutinib is not yet available in China, so patients cannot purchase it domestically and need to purchase it through overseas channels. There are original drugs and generic drugs of bosutinib abroad. The original drugs include the Turkish original drug and the European version of the original drug. The Turkish version of the original drug costs about 2,000 to 3,000 yuan, and the European version of the original drug costs about 30,000 yuan. In addition, there are cheaper generic drugs, which cost more than one thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.